Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Oral Lumicitabine Regimens in Hospitalized Adult Participants Infected With Human Metapneumovirus

Details

Instance of

clinical trial

Start time

5 November 2018

End time

30 April 2019

Country

Argentina, Australia, Brazil, Bulgaria, France, Japan, Malaysia, Netherlands, Poland, Spain, Sweden, Taiwan

Main subject

human metapneumovirus

clinical trial phase

phase II clinical trial

minimum age

18

number of participants

0

research site

Centre Hospitalier Regional Universitaire De Dijon, University at Buffalo, The Queen Elizabeth Hospital, Princess Alexandra Hospital, Royal Melbourne Hospital, Centre hospitalier universitaire de Saint-Étienne, Seoul National University Bundang Hospital, Korea University, Penang General Hospital, University of Groningen, Utrecht University, Kaohsiung Veterans General Hospital

short name

STEP

sponsor

Janssen Pharmaceutica

study type

interventional study

title

A Phase 2b, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Orally Administered Lumicitabine (JNJ-64041575) Regimens in Hospitalized Adult Subjects Infected With Human Metapneumovirus